Chimerix, Inc.'s Antiviral CMX001 Abstract Selected for an Oral...

Chimerix, Inc. 's Antiviral CMX001 Abstract Selected for an Oral Presentation at the European Group for Blood and Marrow Transplantation 's Annual Meeting /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced presentations related to the use of its broad ... (more)

http://www.biospace.com/news_story.aspx?StoryID=291815&full=1